文献速递儿科与产科急症重症综合管理与镇静镇痛心脑血管急症

美国儿童与青少年多系统炎症综合征(MIS-C)与重症急性COVID-19的特征与结局比较

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.
PubMed 文献 · JAMA · 2021-01-01
一句话结论MIS-C与重症COVID-19的临床表型和器官受累模式不同,这些差异可能有助于两者鉴别。

该病例系列纳入2020年3月15日至10月31日美国31个州66家医院收治的1116例21岁以下患者,其中539例(48%)为MIS-C,577例(52%)为重症COVID-19。与COVID-19相比,MIS-C患者更多为6至12岁(40.8% vs 19.4%;aRR 1.51 [95%CI 1.33-1.72])和非西班牙裔黑人(32.3% vs 21.5%;aRR 1.43 [95%CI 1.17-1.76]),更常见心肺受累(56.0% vs 8.8%;aRR 2.99 [95%CI 2.55-3.50])、无呼吸受累的心血管受累(10.6% vs 2.9%;aRR 2.49 [95%CI 2.05-3.02])及无心肺受累的黏膜皮肤受累(7.1% vs 2.3%;aRR 2.29 [95%CI 1.84-2.85])。MIS-C患者中性粒细胞与淋巴细胞比值更高(中位数6.4 vs 2.7,P<.001)、C反应蛋白更高(中位数152 mg/L vs 33 mg/L,P<.001)、血小板计数<150×10³ cells/μL者更多(41% vs 17%,P<.001)。MIS-C患者ICU入住率73.8%,COVID-19为43.8%;住院死亡分别为1.9%和1.4%。MIS-C患者中左心室收缩功能减低者34.2%(172/503),其中91.0%(95%CI 86.0

要点

  • MIS-C与重症COVID-19的器官受累模式不同:MIS-C更多表现为心肺受累(56.0% vs 8.8%;aRR 2.99 [95%CI 2.55-3.50])、无呼吸受累的心血管受累(10.6% vs 2.9%;aRR 2.49)及无心肺受累的黏膜皮肤受累(7.1% vs 2.3%;aRR 2.29),可能有助于床旁鉴别。
  • MIS-C患者炎症标志物更高:中性粒细胞与淋巴细胞比值中位数6.4 vs 2.7(P<.001),C反应蛋白中位数152 mg/L vs 33 mg/L(P<.001),血小板计数<150×10³ cells/μL者41% vs 17%(P<.001)。
  • MIS-C患者ICU入住率73.8%,重症COVID-19为43.8%;住院死亡分别为1.9%和1.4%。
  • MIS-C患者左心室收缩功能减低者34.2%(172/503),其中91.0%(95%CI 86.0%-94.7%)在30天内恢复;冠状动脉瘤者13.4%(57/424),其中79.1%(95%CI 67.1%-89.1%)在30天内恢复。
  • MIS-C患者更多为6至12岁(40.8% vs 19.4%;aRR 1.51 [95%CI 1.33-1.72] vs 0-5岁)和非西班牙裔黑人(32.3% vs 21.5%;aRR 1.43 [95%CI 1.17-1.76] vs 白人)。

适用人群与场景

  • 年龄小于21岁、于2020年3月15日至10月31日在美国31个州66家医院住院的患者。
  • MIS-C患者:有发热、炎症、多系统受累,且SARS-CoV-2 RT-PCR或抗体检测阳性,或近期暴露且无其他诊断。
  • COVID-19患者:SARS-CoV-2 RT-PCR检测阳性且有严重器官系统受累。

研究设计与关键结果

  • 研究设计:病例系列,纳入1116例患者(中位年龄9.7岁;45%女性),其中539例(48%)为MIS-C,577例(52%)为COVID-19;末次随访日期为2021年1月5日。
  • MIS-C vs COVID-19:6至12岁占40.8% vs 19.4%(绝对风险差21.4% [95%CI 16.1%-26.7%];aRR 1.51 [95%CI 1.33-1.72] vs 0-5岁);非西班牙裔黑人占32.3% vs 21.5%(绝对风险差10.8% [95%CI 5.6%-16.0%];aRR 1.43 [95%CI 1.17-1.76] vs 白人)。
  • MIS-C vs COVID-19器官受累:心肺受累56.0% vs 8.8%(绝对风险差47.2% [95%CI 42.4%-52.0%];aRR 2.99 [95%CI 2.55-3.50] vs 呼吸受累);无呼吸受累的心血管受累10.6% vs 2.9%(绝对风险差7.7% [95%CI 4.7%-10.6%];aRR 2.49 [95%CI 2.05-3.02] vs 呼吸受累);无心肺受累的黏膜皮肤受累7.1% vs 2.3%(绝对风险差4.8% [95%CI 2.3%-7.3%];aRR 2.29 [95%CI 1.84-2.85] vs 呼吸受累)。
  • 实验室指标(MIS-C vs COVID-19):中性粒细胞与淋巴细胞比值中位数6.4 vs 2.7(P<.001);C反应蛋白中位数152 mg/L vs 33 mg/L(P<.001);血小板计数<150×10³ cells/μL者212/523(41%)vs 84/486(17%)(P<.001)。
  • 结局:MIS-C患者ICU入住398例(73.8%),COVID-19患者253例(43.8%);住院死亡MIS-C 10例(1.9%),COVID-19 8例(1.4%)。
  • MIS-C患者中,左心室收缩功能减低172/503(34.2%),其中91.0%(95%CI 86.0%-94.7%)在30天内恢复;冠状动脉瘤57/424(13.4%),其中79.1%(95%CI 67.1%-89.1%)在30天内恢复。

证据类型、等级与局限

  • 证据类型:病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,MIS-C与COVID-19的临床表型和器官系统受累模式可能有助于两者鉴别。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Refinement of criteria for multisystem inflammatory syndrome in children (MIS-C) may inform efforts to improve health outcomes.

OBJECTIVE: To compare clinical characteristics and outcomes of children and adolescents with MIS-C vs those with severe coronavirus disease 2019 (COVID-19).

SETTING, DESIGN, AND PARTICIPANTS: Case series of 1116 patients aged younger than 21 years hospitalized between March 15 and October 31, 2020, at 66 US hospitals in 31 states. Final date of follow-up was January 5, 2021. Patients with MIS-C had fever, inflammation, multisystem involvement, and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) or antibody test results or recent exposure with no alternate diagnosis. Patients with COVID-19 had positive RT-PCR test results and severe organ system involvement.

EXPOSURE: SARS-CoV-2.

MAIN OUTCOMES AND MEASURES: Presenting symptoms, organ system complications, laboratory biomarkers, interventions, and clinical outcomes. Multivariable regression was used to compute adjusted risk ratios (aRRs) of factors associated with MIS-C vs COVID-19.

RESULTS: Of 1116 patients (median age, 9.7 years; 45% female), 539 (48%) were diagnosed with MIS-C and 577 (52%) with COVID-19. Compared with patients with COVID-19, patients with MIS-C were more likely to be 6 to 12 years old (40.8% vs 19.4%; absolute risk difference [RD], 21.4% [95% CI, 16.1%-26.7%]; aRR, 1.51 [95% CI, 1.33-1.72] vs 0-5 years) and non-Hispanic Black (32.3% vs 21.5%; RD, 10.8% [95% CI, 5.6%-16.0%]; aRR, 1.43 [95% CI, 1.17-1.76] vs White). Compared with patients with COVID-19, patients with MIS-C were more likely to have cardiorespiratory involvement (56.0% vs 8.8%; RD, 47.2% [95% CI, 42.4%-52.0%]; aRR, 2.99 [95% CI, 2.55-3.50] vs respiratory involvement), cardiovascular without respiratory involvement (10.6% vs 2.9%; RD, 7.7% [95% CI, 4.7%-10.6%]; aRR, 2.49 [95% CI, 2.05-3.02] vs respiratory involvement), and mucocutaneous without cardiorespiratory involvement (7.1% vs 2.3%; RD, 4.8% [95% CI, 2.3%-7.3%]; aRR, 2.29 [95% CI, 1.84-2.85] vs respiratory involvement). Patients with MIS-C had higher neutrophil to lymphocyte ratio (median, 6.4 vs 2.7, P < .001), higher C-reactive protein level (median, 152 mg/L vs 33 mg/L; P < .001), and lower platelet count (<150 ×103 cells/μL [212/523 {41%} vs 84/486 {17%}, P < .001]). A total of 398 patients (73.8%) with MIS-C and 253 (43.8%) with COVID-19 were admitted to the intensive care unit, and 10 (1.9%) with MIS-C and 8 (1.4%) with COVID-19 died during hospitalization. Among patients with MIS-C with reduced left ventricular systolic function (172/503, 34.2%) and coronary artery aneurysm (57/424, 13.4%), an estimated 91.0% (95% CI, 86.0%-94.7%) and 79.1% (95% CI, 67.1%-89.1%), respectively, normalized within 30 days.

CONCLUSIONS AND RELEVANCE: This case series of patients with MIS-C and with COVID-19 identified patterns of clinical presentation and organ system involvement. These patterns may help differentiate between MIS-C and COVID-19.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021. PMID: 33625505. doi:10.1001/jama.2021.2091

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。